Viatris to Acquire Pacira BioSciences in Non-Opioid Pain Push
PCRX sits 37% above its 52-week low of $18.8.
Summary
Viatris has agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing an equity value of $1.65 billion, a move that would make it a leader in non-opioid pain therapies. The deal advances Viatris's innovative medicines strategy and gives it Pacira's EXPAREL franchise, which recently secured a major payer win with UnitedHealthcare. Pacira has been in a proxy battle and recently divested iovera for up to $140M, so this acquisition provides a strategic exit for shareholders. The acquisition is anticipated to close by the end of 2026 and to be immediately accretive to Viatris' financial guidance metrics. The acquisition is subject to customary closing conditions and regulatory approvals. The merger agreement includes a $62.0 million termination fee payable by Pacira under specified circumstances.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The merger agreement includes a $62.0 million termination fee payable by Pacira under specified circumstances.
At the time of this announcement, PCRX was trading at $25.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $18.80 to $27.66. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.